Risk factor
Good trading liquidity
Profitability factor
Very strong margins and returns
About
WuXi AppTec Co., Ltd. operates as an investment holding company, providing extensive research, development, and manufacturing services crucial for the discovery, advancement, and production of both small molecule pharmaceuticals and innovative cell and gene therapies. Its global footprint covers the People's Republic of China, the broader Asian market, the United States, and Europe. The organization is structured into six primary segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi Advanced Therapies Unit (ATU), WuXi Drug Discovery Services Unit (DDSU), and a general 'Others' category. The company offers comprehensive Contract Research, Development, and Manufacturing Organization (CRDMO) services, guiding new drug development from initial discovery stages all the way through to commercialization. This support encompasses a variety of synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates. Furthermore, WuXi AppTec delivers biology services and integrated solutions that assist projects from therapeutic target identification to candidate selection and subsequent progression into clinical phases. The firm also ensures seamless testing services for pharmaceuticals and medical devices, spanning preclinical assessments to full clinical trials. It provides an integrated, end-to-end solution specifically designed to accelerate the time-to-market for cell and gene therapies, alongside broader drug discovery services for pharmaceutical and biotechnology clients, and general clinical research support. Founded in 2000, WuXi AppTec Co., Ltd. maintains its principal offices in Shanghai, People's Republic of China.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is underpriced on P/E, of fair value on EV/EBIT